Nikolas Tripodis - Santen Pharmaceutical Chief Officer
| SNPHF Stock | USD 10.53 0.62 5.56% |
Insider
Nikolas Tripodis is Chief Officer of Santen Pharmaceutical Co
| Phone | 81 6 7664 8621 |
| Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| DVM DVM | Pfizer Inc | 60 | |
| Aamir Malik | Pfizer Inc | 48 | |
| Sally Jackson | GSK plc | N/A | |
| Gordon Loh | Pfizer Inc | N/A | |
| Christopher Stevo | Pfizer Inc | N/A | |
| Montserrat Llamas | Grifols SA ADR | 59 | |
| David Denton | Pfizer Inc | 59 | |
| Sarah EltonFarr | GSK plc | N/A | |
| Julie Brown | GSK plc | 61 | |
| Christopher CFA | Pfizer Inc | N/A | |
| Nuria Lapea | Grifols SA ADR | 60 | |
| Shobie Ramakrishnan | GSK plc | N/A | |
| Mike Mcdermott | Pfizer Inc | N/A | |
| William Gray | Pfizer Inc | N/A | |
| Maria Llano | Grifols SA ADR | 59 | |
| Tony Wood | GSK plc | N/A | |
| William Carapezzi | Pfizer Inc | 63 | |
| Kiyoaki Idemitsu | Ono Pharmaceutical Co | 59 | |
| Diana Conrad | GSK plc | N/A | |
| Jennifer Damico | Pfizer Inc | 56 | |
| Michael Mcdermott | Pfizer Inc | 55 | |
Management Performance
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 |
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satoshi Suzuki, Executive Officer, Chief Director of Planning | ||
| Nobuko Kato, Chief Officer | ||
| Mika Masunari, G Officer | ||
| Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | ||
| Nikolas Tripodis, Chief Officer | ||
| Kaori Itagaki, Gen Group | ||
| Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | ||
| Shinichi Teramachi, Head Officer | ||
| Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | ||
| Ippei Kurihara, Japan Department | ||
| Minori Hara, Chief Officer |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Insiders | 3.21 % | |||
| Shares Owned By Institutions | 53.50 % | |||
| Price To Earning | 14.54 X | |||
| Price To Book | 1.39 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Santen Pink Sheet
Santen Pharmaceutical financial ratios help investors to determine whether Santen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santen with respect to the benefits of owning Santen Pharmaceutical security.